<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002262</url>
  </required_header>
  <id_info>
    <org_study_id>066A</org_study_id>
    <secondary_id>86-989</secondary_id>
    <nct_id>NCT00002262</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma</brief_title>
  <official_title>A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of&#xD;
      intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated&#xD;
      dose (MTD) for single intralesional injections. In addition, to assess the effects of TNF&#xD;
      injections on Kaposi's sarcoma (KS) lesions as measured by P-32 magnetic resonance&#xD;
      spectroscopy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Sarcoma, Kaposi</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tumor Necrosis Factor</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Biopsy-proven Kaposi's sarcoma (KS) with multiple cutaneous lesions.&#xD;
&#xD;
          -  Minimum life expectancy of 3 months.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Clinically significant cardiac disease.&#xD;
&#xD;
          -  Known hemorrhagic diathesis or active bleeding disorder.&#xD;
&#xD;
          -  Clinically apparent vascular disease.&#xD;
&#xD;
          -  Known lipoprotein disorders.&#xD;
&#xD;
          -  History of seizure disorder or central nervous system (CNS) metastasis.&#xD;
&#xD;
          -  Additional malignancy.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Cardiac agents.&#xD;
&#xD;
          -  Anticoagulants.&#xD;
&#xD;
          -  Thrombolytic agents.&#xD;
&#xD;
          -  Nonsteroidal anti-inflammatory drugs.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Aspirin.&#xD;
&#xD;
          -  Vasodilators.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Additional malignancies or other conditions listed in Patient Exclusion Co-Existing&#xD;
             Conditions.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Chemotherapy.&#xD;
&#xD;
          -  Radiotherapy.&#xD;
&#xD;
          -  Immunotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1988</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Skin Neoplasms</keyword>
  <keyword>Tumor Necrosis Factor</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

